Dyne Therapeutics (DYN) Stock Price, News & Analysis

Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $11.67 to $12.34
• 50-Day Range: $6.81 to $12.56
• 52-Week Range: $6.36 to $47.45
• Volume: 1.58 million shs
• Average Volume: 1.63 million shs
• Market Capitalization: $1.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.15
• Consensus Rating: Buy

Dyne Therapeutics Stock Analysis - MarketRank™

Dyne Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 436th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Dyne Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyne Therapeutics is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyne Therapeutics is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyne Therapeutics has a P/B Ratio of 8.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

28.77% of the float of Dyne Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Dyne Therapeutics has recently increased by 56.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyne Therapeutics does not currently pay a dividend.

Dividend Growth

Dyne Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

28.77% of the float of Dyne Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Dyne Therapeutics has recently increased by 56.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.38

News Sentiment

Dyne Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Dyne Therapeutics this week, compared to 7 articles on an average week.

MarketBeat Follows

Only 4 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,518.00 in company stock.

Percentage Held by Insiders

14.14% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DYN Stock Analysis - Frequently Asked Questions

How have DYN shares performed this year?

Dyne Therapeutics' stock was trading at $23.56 at the beginning of the year. Since then, DYN stock has decreased by 48.0% and is now trading at $12.24.
View the best growth stocks for 2025 here.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its earnings results on Thursday, May, 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.17.

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' top institutional investors include RA Capital Management L.P. (8.55%), Atlas Venture Life Science Advisors LLC (8.03%), Vanguard Group Inc. (6.52%) and Braidwell LP (3.19%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, Oxana Beskrovnaya, Wildon Farwell, Jonathan Mcneill, Susanna Gatti High, Richard William Scalzo, Dirk Kersten, Johanna Friedl-Naderer, John Cox and Carlo Incerti.
View institutional ownership trends.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dyne Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DYN
• Previous Symbol: NYSE:DYN
• CIK: 1818794
• Web: www.dyne-tx.com
• Phone: 781-786-8230
• Fax: 781-786-8866
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.15
• High Stock Price Target: $66.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +284.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.07
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$235.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.46%
• Return on Assets: -51.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.02
• Quick Ratio: 17.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.49 per share
• Price / Book: 8.23

Miscellaneous

• Outstanding Shares: 113,667,000
• Free Float: 80,629,000
• Market Cap: $1.39 billion
• Optionable: Optionable
• Beta: 1.19